Aim at 1 billion yuan left oxyfluorosa star eye preparation market, another drug enterprise power.

Pharmaceutical Network Industry Dynamics, Wuhan Noan Pharmaceutical's left-oxygen fluorosala-saffer 4 class of imitation listing application was accepted.
-meter net data show that in recent years, the sales of left-oxygen fluorosatin eye preparations in China's public medical institutions, the end-of-the-line sales of rapid growth, in 2019 exceeded the 1 billion yuan mark, an increase of nearly 20% year-on-year.
from the 2019 China public medical institutions terminal left oxyfluorosaxon eye preparation market pattern, the market share of the pharmaceutical industry reached 60.44 percent, followed by the Federal Pharmaceuticals, Hangzhou Guoguang Pharmaceuticals, Yabang Pharmaceuticals, respectively, 5.82%, 5.72% and 4.38%.
note that the market share of The Pharmaceuticals declined from 66.16 percent in 2015 to 60.44 percent in 2019 as domestic pharmaceutical companies grew.
the current number of left-oxygen fluorosa-sand eye drops over-evaluation enterprises, respectively, Yangzijiang and Zhongshan Wanhan, are approved with imitation 4 categories of declaration, as passed by consistency evaluation.
its sales reached 749.99 million yuan in public medical facilities in 2019, a growth rate of 20.27 percent, second only to the 1.2 billion yuan of sodium glass acid drophole.
, Yang Zijiang Pharmaceutical's left oxyfluorosa star eye drops and sodium vitate eye drops in the domestic market accounted for an increase.
the clinical application of the left oxyfluorosastar eye drops, the market potential is large, which also attracts more enterprises to focus on the layout.
currently under review to the new registration classification of the production of left-oxygen fluorosa star eye drops enterprises have 4, including Beijing Huienland Pharmaceuticals, Sichuan Yiyi Pharmaceutical, Shenyang Xingqi Eye Medicine, Sichuan Meida Kanghuakang.
from the morning and evening of the hosting time, Sichuan Meida Kang Huakang as early as November 12, 2018 to receive the hosting, Beijing Huienland Pharmaceuticals was hosted on June 10 this year.
-meter net data show that the current Xingqi eye medicine, left-oxygen fluorosalin eye drops and other 4 products submitted by the newly registered classification of the listing application in the review, once approved will be treated as a consistency evaluation.
in recent years, with the continuous growth of the number of people with myopia, eye fatigue patients increased, the domestic ophthalmology drug market continues to grow.
Minet data show that in 2019 China's public medical institutions terminal eye preparations (eye drops, eye cream, eye gels, etc.) market size of nearly 7 billion yuan, an increase of 14.83 percent year-on-year.
18 of the top 20 products sold were eye drops.
in addition to the left oxyfluorosa star eye drops, sodium glass acid eye drops sales of up to 1.2 billion yuan, followed by Pralovin eye drops, tubmycin desemethan eye drops, hydrochloric acid left oxyfluorosaosin eye drops and so on.
2019, 11 of the top 15 categories of sales increased year-on-year in 2018, with the growth rate of olotatic ootted eye drops at hydrochloric acid of 45.61 percent.
from the variety of the situation, in addition to the left oxyfluorasin eye drops, sodium vitate eye drops, hydrochloric acid Olota fixed eye drops, crankprosine eye drops 3 varieties have also been evaluated by enterprises.
of which sodium glass acid drop eye drops over-rated enterprises full of 3.
from the enterprise review situation, Zhongshan Wanhan Pharmaceutical, Chengdu Push Pharmaceuticals each have 2 eye drops over review, the rest have 1 eye drops over review.
in addition from the number of declared enterprises, hydrochloric acid Moxisha star eye drops have 10 enterprises to the new classification of production, the product is currently only in the domestic original research drug on sale;
.